Biomedical Technology Institute (BMTI),
Twente University, The Netherlands

The Biomedical Technology Institute (BMTI) is the institute of the University of Twente where all research activities in the (bio) medical field are brought together. BMTI aims at improving the quality of life of human beings, by restoring body performance whenever there is a need to, because of loss of function through diseases, accidents or more age-related deterioration of human functioning.

In October 2003, the transfer of the IsoTis in-house orthobiology research group to the University of Twente was announced and the group became part of the BMTI. The research group will focus on the biology and repair of musculo-skeletal tissues and bioreactor technology, which is being developed in order to culture stem cells on a reproducible and controlled manner.

Department of Materials & IRC in Biomedical Engineering,
Queen Mary University of London, United Kingdom

Biomaterials and tissue engineering are key disciplines of the Materials Department and the IRC in Biomedical Engineering at Queen Mary University of London. Several departments and interdisciplinary groups are working on these topics from a materials science & engineering, biology or medical perspective. Especially knowledge is available on the fabrication of various biomaterials and mesenchymal stem cell culture technology for the repair and regeneration of musculo-skeletal tissues.

Applikon Biotechnology, The Netherlands

Applikon Biotechnology is specialised in the design, engineering and manufacturing of bioreactors, control systems and software. Designs are according the latest standards for equipment used in the Life Science industry (cGMP / GAMP). The Applikon systems are highly valued in this industry, both in R&D, process development and pilot plants. In the product portfolio there are micro reactors, mini reactors, single-use reactors, glass (autoclavable) and stainless steel (Steam-In-Place) bioreactors. The reactor volumes are ranging from 3ml – 2000L and include complete measurement and control (including SCADA). Innovative sensors and a unique cell retention device (perfusion) complete the portfolio. In the development and design of an adult stem cell expansion sytem, Applikon Biotechnology and Progentix have a strong collaboration.

Progentix is looking for partners

Progentix is looking for partners interested in further developing its stem cell technology in the orthobiology market, as well as for orthopaedic companies for the further commercialisation of its unique portfolio of synthetic bone grafts.

For non-orthobiology applications, Progentix is looking for:

• partners interested in the further development of its adult stem cell technology in clinical areas such as cardiovascular and neural disease
• partners interested in the commercialisation of Progentix’ expanded stem cells for R&D purposes
• prospective buyers of its expanded stem cells (universities, research institutes and companies).

Progentix is further able to provide fully characterised expanded adult stem cells, specific culture medium and supplements for the expansion and osteogenic differentiation of adult stem cells, and a unique group of synthetic biomaterial scaffolds.